Bedrijfsoverzicht
Incyte Corporation is a biopharmaceutical enterprise dedicated to the discovery, development, and commercialization of therapeutics across the United States, Europe, Canada, and Japan, specifically focusing on areas such as myelofibrosis and polycythemia vera. The company operates within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized player in the pharmaceutical landscape that targets specific medical conditions. Currently, the entity maintains a substantial scale with a market capitalization of $19.12 billion, generating $5.14 billion in annual revenue, and employing a workforce of 2,844 individuals. These financial metrics, particularly the market cap exceeding $19 billion, indicate that Incyte Corporation holds a significant position within the biotechnology sector, reflecting strong market confidence and substantial operational reach. The revenue figure of $5.14 billion further underscores the company's established commercial footprint, allowing it to fund extensive research and development activities alongside global commercialization efforts.
Financiële gezondheid
Incyte Corporation reported a trailing twelve-month revenue of $5.14 billion, accompanied by a net income of $1.29 billion and an EBITDA of $1.44 billion. The notable gap between the $5.14 billion in revenue and the $1.29 billion in net income reveals a cost structure where operating expenses, including research and development, sales, and administrative costs, consume approximately 74.8% of total revenue before arriving at the bottom line. The company generated $609.55 million in free cash flow, which signifies robust financial flexibility to fund ongoing operations, pursue strategic acquisitions, or invest in new therapeutic pipelines without relying heavily on external capital markets. Profitability is further highlighted by a gross margin of 52.9%, an operating margin of 25.6%, and a profit margin of 25.0%, all of which indicate efficient cost management relative to the high-cost nature of the biotechnology industry. On the balance sheet, the company holds $3.58 billion in cash against a debt load of only $54.92 million, resulting in a conservative financial posture supported by a debt-to-equity ratio of 1.06. Liquidity is exceptionally strong as evidenced by a current ratio of 3.32, suggesting the company possesses more than three times the current assets necessary to cover its short-term liabilities. Return on equity stands at 29.9% while return on assets is 13.6%, metrics that collectively reveal highly effective management in generating returns on shareholder capital and utilizing total assets to drive profitability.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is 14.99, while the forward P/E stands at 11.11, implying that the market expects earnings growth that will cause the forward multiple to be lower than the historical trailing average. The price-to-book ratio is 3.69, indicating that the market values the company at a significant premium over its net book value, likely due to the intangible assets inherent in biotechnology such as patents and intellectual property. Alternative valuation metrics such as a price-to-sales ratio of 3.72 and an EV/EBITDA of 10.83 suggest that investors are pricing the stock based on future growth potential rather than current asset base or immediate earnings alone. Regarding trading ranges, the stock has a 52-week high of $112.29 and a 52-week low of $56.13; without a specific current share price provided in the facts, the valuation is analyzed within the context of this $56.13 to $112.29 range. The beta value of 0.86 indicates that the stock's price volatility is lower than the broader market, suggesting that Incye Corporation's share price tends to move with less intensity than the overall market index.
Growth & Income
Revenue growth year-over-year stands at 27.8%, while earnings growth year-over-year reaches 43.6%, demonstrating that earnings are growing at a significantly faster pace than revenue. This divergence implies that the company is benefiting from favorable pricing, cost efficiencies, or a high-margin product mix that amplifies bottom-line growth relative to top-line expansion. As a non-dividend payer, Incyte Corporation does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company retains all net income to reinvest into growth initiatives rather than distributing cash to shareholders. The overall growth and income profile is characterized by rapid double-digit expansion in profitability and a strategic decision to prioritize capital allocation toward future development over current income distribution to shareholders.